A synthetic cryptochrome inhibitor induces anti-proliferative effects and increases chemosensitivity in human breast cancer cells.

[1]  D. Kojetin,et al.  Anti-proliferative actions of a synthetic REV-ERBα/β agonist in breast cancer cells. , 2015, Biochemical pharmacology.

[2]  E. Wiemer,et al.  Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients , 2015, Breast Cancer Research and Treatment.

[3]  J. Lee,et al.  Circadian Clock, Cancer, and Chemotherapy , 2014, Biochemistry.

[4]  Sooyoung Chung,et al.  Impact of Circadian Nuclear Receptor REV-ERBα on Midbrain Dopamine Production and Mood Regulation , 2014, Cell.

[5]  Sooyoung Chung,et al.  Identification and validation of cryptochrome inhibitors that modulate the molecular circadian clock. , 2014, ACS chemical biology.

[6]  Peng Huang,et al.  Overexpression of the Circadian Clock Gene Bmal1 Increases Sensitivity to Oxaliplatin in Colorectal Cancer , 2013, Clinical Cancer Research.

[7]  Helge Kjuus,et al.  Analysis of polymorphisms in the circadian-related genes and breast cancer risk in Norwegian nurses working night shifts , 2013, Breast Cancer Research.

[8]  J. Lee,et al.  DNA damage-specific control of cell death by cryptochrome in p53-mutant ras-transformed cells. , 2013, Cancer research.

[9]  J. Minna,et al.  The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma , 2012, International journal of cancer.

[10]  Peter C. St. John,et al.  Identification of Small Molecule Activators of Cryptochrome , 2012, Science.

[11]  Logan J Everett,et al.  Rev-erbα and Rev-erbβ coordinately protect the circadian clock and normal metabolic function. , 2012, Genes & development.

[12]  J. Takahashi,et al.  Regulation of Circadian Behavior and Metabolism by Synthetic REV-ERB Agonists , 2012, Nature.

[13]  D. Kojetin,et al.  Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB. , 2011, ACS chemical biology.

[14]  L. Xian,et al.  Effects of the biological clock gene Bmal1 on tumour growth and anti-cancer drug activity. , 2010, Journal of biochemistry.

[15]  R. Stevens,et al.  Phenotypic effects of the circadian gene Cryptochrome 2 on cancer-related pathways , 2010, BMC Cancer.

[16]  T. Holford,et al.  The Core Circadian Gene Cryptochrome 2 Influences Breast Cancer Risk, Possibly by Mediating Hormone Signaling , 2010, Cancer Prevention Research.

[17]  Kathryn Moynihan Ramsey,et al.  Circadian Rhythms and Metabolic Syndrome: From Experimental Genetics to Human Disease , 2010, Circulation research.

[18]  Jean Clairambault,et al.  Circadian timing in cancer treatments. , 2010, Annual review of pharmacology and toxicology.

[19]  T. Ritz,et al.  Cryptochrome , 2010, Communicative & integrative biology.

[20]  J. Lee,et al.  Loss of cryptochrome reduces cancer risk in p53 mutant mice , 2009, Proceedings of the National Academy of Sciences.

[21]  Sooyoung Chung,et al.  Adrenal peripheral clock controls the autonomous circadian rhythm of glucocorticoid by causing rhythmic steroid production , 2008, Proceedings of the National Academy of Sciences.

[22]  Erin L. McDearmon,et al.  The genetics of mammalian circadian order and disorder: implications for physiology and disease , 2008, Nature Reviews Genetics.

[23]  S. Hill,et al.  Period-2: a tumor suppressor gene in breast cancer , 2008, Journal of circadian rhythms.

[24]  R. Virk,et al.  The clock gene Per2 links the circadian system to the estrogen receptor , 2007, Oncogene.

[25]  I. Andrulis,et al.  Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors. , 2007, Neoplasia.

[26]  P. Chomczyński,et al.  The single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction: twenty-something years on , 2006, Nature Protocols.

[27]  F. Halberg,et al.  Circadian gene mPer2 overexpression induces cancer cell apoptosis , 2006, Cancer science.

[28]  H. Oster.  The genetic basis of circadian behavior , 2006, Genes, brain, and behavior.

[29]  Aziz Sancar,et al.  Cryptochrome, circadian cycle, cell cycle checkpoints, and cancer. , 2005, Cancer research.

[30]  Fred W. Turek,et al.  Obesity and Metabolic Syndrome in Circadian Clock Mutant Mice , 2005, Science.

[31]  Aziz Sancar,et al.  Coupling of Human Circadian and Cell Cycles by the Timeless Protein , 2005, Molecular and Cellular Biology.

[32]  Paolo Sassone-Corsi,et al.  Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  S. Yamaguchi,et al.  Control Mechanism of the Circadian Clock for Timing of Cell Division in Vivo , 2003, Science.

[34]  Peng Huang,et al.  The Circadian Gene Period2 Plays an Important Role in Tumor Suppression and DNA Damage Response In Vivo , 2002, Cell.

[35]  S. Reppert,et al.  Coordination of circadian timing in mammals , 2002, Nature.

[36]  F Laden,et al.  Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. , 2001, Journal of the National Cancer Institute.

[37]  S. Kay,et al.  Time zones: a comparative genetics of circadian clocks , 2001, Nature Reviews Genetics.

[38]  Johnni Hansen,et al.  Increased Breast Cancer Risk among Women Who Work Predominantly at Night , 2001, Epidemiology.

[39]  Steven M Reppert,et al.  mCRY1 and mCRY2 Are Essential Components of the Negative Limb of the Circadian Clock Feedback Loop , 1999, Cell.

[40]  D. P. King,et al.  Mammalian Circadian Autoregulatory Loop A Timeless Ortholog and mPer1 Interact and Negatively Regulate CLOCK-BMAL1-Induced Transcription , 1998, Neuron.

[41]  T. Hirota,et al.  Identification of small-molecule modulators of the circadian clock. , 2015, Methods in enzymology.

[42]  A. Hall,et al.  of the circadian clock , 2007 .

[43]  G. Houin,et al.  Chronopharmacokinetics of doxorubicin in patients with breast cancer , 2004, European Journal of Clinical Pharmacology.